How should we use calcineurin inhibitors in myasthenia gravis?

Hiroyuki Murai

Research output: Contribution to journalReview article

Abstract

Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.

Original languageEnglish
Pages (from-to)118-119
Number of pages2
JournalClinical and Experimental Neuroimmunology
Volume6
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Myasthenia Gravis
Japan
Calcineurin Inhibitors
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology

Cite this

How should we use calcineurin inhibitors in myasthenia gravis? / Murai, Hiroyuki.

In: Clinical and Experimental Neuroimmunology, Vol. 6, No. 2, 01.01.2015, p. 118-119.

Research output: Contribution to journalReview article

@article{4e73b514cc0a4f01808307d84a5f25f2,
title = "How should we use calcineurin inhibitors in myasthenia gravis?",
abstract = "Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.",
author = "Hiroyuki Murai",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/cen3.12206",
language = "English",
volume = "6",
pages = "118--119",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - How should we use calcineurin inhibitors in myasthenia gravis?

AU - Murai, Hiroyuki

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.

AB - Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.

UR - http://www.scopus.com/inward/record.url?scp=84928945800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928945800&partnerID=8YFLogxK

U2 - 10.1111/cen3.12206

DO - 10.1111/cen3.12206

M3 - Review article

AN - SCOPUS:84928945800

VL - 6

SP - 118

EP - 119

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 2

ER -